Eltrombopag for Peripheral Blood Stem Cell Harvest
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorNational Taiwan University Hospital
About this trial
The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are:
* Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest. * Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization.
Participants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.
Eligibility criteria
Qualifiers
Age: ≥ 18 years
Diagnosis: Hodgkin lymphoma or non-Hodgkin lymphoma
Disease status: complete response, partial response, or stable disease after at least 2 cycles of treatment (see appendix 2 for definition)
Planned to receive ESHAP (etoposide, steroid, high-dose cytarabine, cisplatin) chemotherapy with/without monoclonal antibody (ex: rituximab, brentuximab) as chemo-mobilization for stem cell harvest
Disqualifiers
History of vascular thromboembolic event
Steady state platelet count > 1000k/μL
Documented cytogenetic abnormalities in marrow blood
Current administration of eltrombopag
Trial design
Treatments tested in this trial
- Eltrombopag olamine
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
National Taiwan University Hospital
Lead sponsor
Novartis
Collaborator
Source ClinicalTrials.gov